MTX-474 aims to neutralise the EphrinB2 signalling that causes fibrosis onset and progression. Credit: Chinnapong / Shutterstock.

Mediar Therapeutics has dosed the first patient as part of a Phase I clinical trial evaluating MTX-474, a first-in-class human IgG1 antibody aimed at halting fibrosis progression.

MTX-474 aims to neutralise the EphrinB2 signalling that causes fibrosis onset and progression.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The clinical trial, taking place in Australia, will evaluate the tolerability, safety, pharmacokinetics, and target engagement of MTX-474 in healthy volunteers.

It will be assessed through single ascending and multiple ascending dose cohorts.

The company is concurrently advancing its US Phase I trial of MTX-463, another first-in-class antibody targeting WNT1-inducible signalling pathway protein-1 (WISP1), with the majority of cohorts already dosed.

This trial is expected to conclude by the end of this year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

MTX-463 has shown promising results in vitro and in preclinical mouse models, reducing fibrosis across several indications.

The Phase I study for MTX-463 aims to assess its safety at multiple dose levels, tolerability, and pharmacokinetics of the antibody. It will also evaluate the antibody’s ability to engage its target, WISP-1.

The antibody received orphan drug and fast-track designations from the Food and Drug Administration (FDA).

Mediar Therapeutics CEO Rahul Ballal said: “Dosing participants in our MTX-474 trial marks another important milestone for Mediar and, alongside our ongoing Ph-1 MTX-463 study, opens new potential pathways to target fibrosing diseases.

“Furthermore, the FDA granting both orphan drug and fast track designations for MTX-463 emphasises the potential of this novel therapy to address the high unmet need in IPF.”